Fifth Third Bancorp
EWTX icon

Fifth Third Bancorp’s Edgewise Therapeutics EWTX Stock Holding History

Fifth Third Bancorp’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.83K Buy
193
+160
+485% +$5.52K ﹤0.01% 3812
2026
Q1 		$1.04K Buy
+33
New +$952 ﹤0.01% 4125

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fifth Third Bancorp's EWTX Position: Q2 2026 in Review

Fifth Third Bancorp increased its Edgewise Therapeutics (EWTX) stake by 485% in Q2 2026, buying an estimated $5.52K and bringing the position to 193 shares worth $7.83K. The position accounts for ﹤0.01% of the portfolio, ranked #3812.

Fifth Third Bancorp first reported a position in EWTX in Q1 2026 and has held it in 2 quarters since. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Fifth Third Bancorp held 193 shares of Edgewise Therapeutics worth $7.83K as of Q2 2026.
  • Fifth Third Bancorp bought 160 Edgewise Therapeutics shares in Q2 2026, an estimated $5.52K.
  • Edgewise Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #3812 holding.
  • Fifth Third Bancorp first reported a position in Edgewise Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.